The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 28, 2015

Filed:

Jul. 31, 2012
Applicants:

Guisen Zhang, Xuzhou, CN;

Yin Chen, Jiangsu, CN;

Xiangqing Xu, Jiangsu, CN;

Xin Liu, Hubei, CN;

Song Zhao, Jiangsu, CN;

Bifeng Liu, Hubei, CN;

Minquan Yu, Jiangsu, CN;

Yinli Qiu, Jiangsu, CN;

Inventors:

Guisen Zhang, Xuzhou, CN;

Yin Chen, Jiangsu, CN;

Xiangqing Xu, Jiangsu, CN;

Xin Liu, Hubei, CN;

Song Zhao, Jiangsu, CN;

Bifeng Liu, Hubei, CN;

Minquan Yu, Jiangsu, CN;

Yinli Qiu, Jiangsu, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/496 (2006.01); A61K 31/453 (2006.01); A61K 31/454 (2006.01); C07D 311/94 (2006.01); C07D 405/12 (2006.01); C07D 417/12 (2006.01); C07D 417/14 (2006.01); C07D 413/14 (2006.01); C07D 311/80 (2006.01); C07D 409/12 (2006.01);
U.S. Cl.
CPC ...
C07D 311/94 (2013.01); C07D 417/14 (2013.01); A61K 31/496 (2013.01); A61K 31/454 (2013.01); A61K 31/453 (2013.01); C07D 413/14 (2013.01); C07D 311/80 (2013.01); C07D 405/12 (2013.01); C07D 417/12 (2013.01); C07D 409/12 (2013.01);
Abstract

Disclosed are alicyclic[c]benzopyrone derivatives and use thereof. The alicyclic[c]benzopyrone derivatives are compounds represented by formula I or their salts. The present compounds not only significantly improve high activity induced by MK-801, but also effectively improve clambering symptom induced by Apomorphine and do not cause EPS within effective dose. These in vitro targets and in vivo pharmacological models are closely related to diseases of the nervous system caused by dopamine dysfunction, especially schizophrenia. Therefore the present compounds can be used for the treatment of central nervous system diseases, especially schizophrenia. EDis lower and effect is stronger in two animal models i.e. high activity induced by MK-801 and clambering symptom induced by Apomorphine, while EDis higher and therapeutic index is greater in animal models of catalepsy.


Find Patent Forward Citations

Loading…